

17/18


Response Under 37 C.F.R. § 1.116
Expedited Procedure-
Examining Group 1625
Attorney's Docket No. N0260/7031 (ERG)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Nigel L. Webb, et al.
Serial No. : 09/265,307
Filing Date : March 9, 1999
For : FATTY ACID-ANTICANCER CONJUGATES AND USES THEREOF
Examiner : B. Trinh
Art Group : 1625

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to the Box RCE, Commissioner for Patents, Washington, D.C. 20231, on the 22nd day of October, 2001.


Edward R. Gates

Box RCE
Commissioner for Patents
Washington, D.C. 20231

Sir:

AMENDMENT

A three month extension of time, from July 20, 2001 to October 20, 2001, is requested for response to the final Office Action mailed from the Patent Office on April 20, 2001.

In the Claims:

1. (amended) A fatty acid-anticancer compound conjugate composition for administration to a subject, comprising at least one fatty acid-anticancer compound conjugate in a container for administration to a subject, wherein the amount of the fatty acid-anticancer compound in the container is at least about 10% on a molar basis greater than the maximum tolerated dose (MTD) in the subject for the unconjugated at least one anticancer compound, wherein the container is a container for intravenous administration.

Please add the following claims:

569398.1